JP2023543152A5 - - Google Patents
Info
- Publication number
- JP2023543152A5 JP2023543152A5 JP2023516061A JP2023516061A JP2023543152A5 JP 2023543152 A5 JP2023543152 A5 JP 2023543152A5 JP 2023516061 A JP2023516061 A JP 2023516061A JP 2023516061 A JP2023516061 A JP 2023516061A JP 2023543152 A5 JP2023543152 A5 JP 2023543152A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063080172P | 2020-09-18 | 2020-09-18 | |
| US63/080,172 | 2020-09-18 | ||
| PCT/US2021/050850 WO2022061098A1 (en) | 2020-09-18 | 2021-09-17 | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543152A JP2023543152A (ja) | 2023-10-13 |
| JP2023543152A5 true JP2023543152A5 (https=) | 2025-09-30 |
Family
ID=78135158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516061A Pending JP2023543152A (ja) | 2020-09-18 | 2021-09-17 | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11905332B2 (https=) |
| EP (1) | EP4214234A1 (https=) |
| JP (1) | JP2023543152A (https=) |
| KR (1) | KR20230070259A (https=) |
| CN (1) | CN116348495A (https=) |
| AU (1) | AU2021345262A1 (https=) |
| CA (1) | CA3191839A1 (https=) |
| CL (3) | CL2023000761A1 (https=) |
| CO (1) | CO2023004448A2 (https=) |
| IL (1) | IL301037A (https=) |
| MX (1) | MX2023003214A (https=) |
| WO (1) | WO2022061098A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279354B1 (en) * | 2018-06-21 | 2026-02-01 | Regeneron Pharma | Bispecific antibodies against psma and against cd28 and their uses |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| MX2023003214A (es) | 2020-09-18 | 2023-05-24 | Regeneron Pharma | Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| US20230416396A1 (en) * | 2022-05-18 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| US20240228620A1 (en) | 2022-10-06 | 2024-07-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| WO2025027003A1 (en) * | 2023-07-31 | 2025-02-06 | Sanofi | Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas |
| WO2025026356A1 (zh) * | 2023-07-31 | 2025-02-06 | 百奥泰生物制药股份有限公司 | 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
| CN119101160B (zh) * | 2024-10-25 | 2025-02-11 | 江苏百英生物科技有限公司 | 一种抗cd28纳米抗体、基于天然库筛选cd28纳米抗体的方法及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CA3020633A1 (en) * | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| BR112020007002A2 (pt) * | 2017-10-10 | 2020-11-17 | Sanofi | anticorpos anti-cd38 e métodos de uso |
| IL279354B1 (en) * | 2018-06-21 | 2026-02-01 | Regeneron Pharma | Bispecific antibodies against psma and against cd28 and their uses |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MA54540A (fr) * | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
| US11453721B2 (en) * | 2018-12-19 | 2022-09-27 | Regeneran Pharmaceuticals, Inc. | Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof |
| UA128001C2 (uk) * | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
| MX2023003214A (es) | 2020-09-18 | 2023-05-24 | Regeneron Pharma | Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas. |
-
2021
- 2021-09-17 MX MX2023003214A patent/MX2023003214A/es unknown
- 2021-09-17 JP JP2023516061A patent/JP2023543152A/ja active Pending
- 2021-09-17 EP EP21791138.7A patent/EP4214234A1/en active Pending
- 2021-09-17 IL IL301037A patent/IL301037A/en unknown
- 2021-09-17 AU AU2021345262A patent/AU2021345262A1/en active Pending
- 2021-09-17 US US17/477,870 patent/US11905332B2/en active Active
- 2021-09-17 KR KR1020237012986A patent/KR20230070259A/ko active Pending
- 2021-09-17 CN CN202180068348.2A patent/CN116348495A/zh active Pending
- 2021-09-17 CA CA3191839A patent/CA3191839A1/en active Pending
- 2021-09-17 WO PCT/US2021/050850 patent/WO2022061098A1/en not_active Ceased
-
2023
- 2023-03-16 CL CL2023000761A patent/CL2023000761A1/es unknown
- 2023-04-11 CO CONC2023/0004448A patent/CO2023004448A2/es unknown
-
2024
- 2024-01-23 US US18/420,588 patent/US12590168B2/en active Active
-
2025
- 2025-01-16 CL CL2025000134A patent/CL2025000134A1/es unknown
- 2025-10-07 CL CL2025003055A patent/CL2025003055A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543152A5 (https=) | ||
| US11692035B2 (en) | Therapeutic CD47 antibodies | |
| JP2021531005A5 (https=) | ||
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| FI3823664T3 (fi) | Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä | |
| JP2021518103A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2021524249A5 (https=) | ||
| JP2022526764A5 (https=) | ||
| JP7170331B2 (ja) | 固形及び血液癌の治療のための併用療法 | |
| US20170015758A1 (en) | Compositions And Methods For Modulating And Redirecting Immune Responses | |
| JP2022510964A5 (https=) | ||
| JP2021506244A5 (https=) | ||
| AU2018348429A1 (en) | Multispecific antibody | |
| EP2262837A2 (en) | Pd-1 binding proteins | |
| US20190309066A1 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| US20220313819A1 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| JP2021520201A5 (https=) | ||
| WO2020198370A2 (en) | Therapeutic cd47 antibodies | |
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| WO2021263085A2 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| RU2025113775A (ru) | Биспецифические антитела против cd3 и cd20 собаки | |
| CN121620534A (zh) | 抗tigit抗体及其用途 |